NK cells augment oncolytic adenovirus cytotoxicity in ovarian cancer

Leung, Elaine Y.I.; Ennis, Darren P.; Kennedy, Philippa R.; Hansell, Christopher; Dowson, Suzanne; Farquharson, Malcolm; Spiliopoulou, Pavlina; Nautiyal, Jaya; McNamara, Sophie; Carlin, Leo M.; Fisher, Kerry; Davis, Daniel M.; Graham, Gerard; Mcneish, Iain A.

DOI: 10.1016/j.omto.2020.02.001

License: Creative Commons: Attribution (CC BY)

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (Harvard):
Leung, EYL, Ennis, DP, Kennedy, PR, Hansell, C, Dowson, S, Farquharson, M, Spiliopoulou, P, Nautiyal, J, McNamara, S, Carlin, LM, Fisher, K, Davis, DM, Graham, G & Mcneish, IA 2020, 'NK cells augment oncolytic adenovirus cytotoxicity in ovarian cancer', Molecular Therapy - Oncolytics, vol. 16, pp. 289-301. https://doi.org/10.1016/j.omto.2020.02.001

Link to publication on Research at Birmingham portal

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.
• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
• User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
• Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.
NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer

Elaine Y.L. Leung,1,2 Darren P. Ennis,1,3 Philippa R. Kennedy,4 Christopher Hansell,2 Suzanne Dowson,1 Malcolm Farquharson,1 Pavlina Spiliopoulou,1,3 Jaya Nautiyal,3 Sophie McNamara,3 Leo M. Carlin,5 Kerry Fisher,6 Daniel M. Davis,4 Gerard Graham,2 and Iain A. McNeish1,3

1Institute of Cancer Sciences, University of Glasgow, Glasgow, UK; 2Institute of Infection, Inflammation and Immunity, University of Glasgow, Glasgow, UK; 3Ovarian Cancer Action Research Centre and Division of Cancer, Department of Surgery and Cancer, Imperial College, London, UK; 4Manchester Collaborative Centre for Inflammation Research, University of Manchester, Manchester, UK; 5Cancer Research UK Beatson Institute, Glasgow, UK; 6PsiOxus Therapeutics, Oxford, UK

Oncolytic viruses (OVs) can trigger profound innate and adaptive immune responses, which have the potential both to potentiate and reduce the activity of OVs. Natural killer (NK) cells can mediate potent anti-viral and anti-tumoral responses, but there are no data on the role of NK cells in oncolytic adenovirus activity. Here, we have used two different oncolytic adenoviruses—the Ad5 E1A CR2-deletion mutant d922-947 (group C) and the chimeric Ad3/Ad11p mutant enadenotucirev (group B)—to investigate the effect of NK cells on overall anti-cancer efficacy in ovarian cancer. Because human adenoviruses do not replicate in murine cells, we utilized primary human NK cells from peripheral blood and ovarian cancer ascites. Our results show that d922-947 and enadenotucirev do not infect NK cells, but induce contact-dependent activation and anti-cancer cytotoxicity against adenovirus-infected ovarian cancer cells. Moreover, manipulation of NK receptors DNAM-1 (DNAX accessory molecule-1) and TIGIT (T cell immunoreceptor with Ig and ITIM domains) significantly influences NK cytotoxicity against adenovirus-infected cells. Together, these results indicate that NK cells act to increase the activity of oncolytic adenovirus in ovarian cancer and suggest that strategies to augment NK activity further via the blockade of inhibitory NK receptor TIGIT could enhance therapeutic potential of OVs.

INTRODUCTION

Oncolytic viruses (OVs) infect malignant cells and replicate selectively within them. This selective replication induces direct cytotoxicity and also triggers profound innate and adaptive immune responses,1–3 which have the potential both to potentiate and reduce the anti-cancer activity of the OVs.4

Oncolytic adenoviruses have shown potential as cancer therapeutics in multiple pre-clinical tumor models,5–7 and the first oncolytic virus licensed for routine clinical practice was an adenovirus.8 Two oncolytic adenoviruses were evaluated in this work: the E1A CR2-deleted Ad5 mutant d922-947, which we have previously shown has significant efficacy in ovarian cancer models,9,10 and the chimeric Ad3/Ad11p mutant enadenotucirev, which was generated by directed evolution and is currently being tested in early phase clinical trials in ovarian (ClinicalTrials.gov: NCT02053220)12 and other cancers (ClinicalTrials.gov: NCT02028117).

Natural killer (NK) cells are a group of effector innate immune cells that can mediate potent anti-viral and anti-tumoral responses (reviewed in Jos and Altfeld13 and Marcus et al.14). In the context of oncolytic virotherapy, NK cells activated by the viral infection could potentially lead to efficient elimination of the infected cancer cells, but rapid clearance of virus-infected cells may also prevent the spread of OVs and reduce overall activity. Previous studies suggested that NK cells are activated by oncolytic reovirus treatment in patients15 and are necessary for successful maraba virus therapy in murine models.16 By contrast, NK cells may limit the efficacy of an oncolytic herpes simplex virus 1 (HSV-1) in murine glioblastoma models,17 which may be reversed by transforming growth factor-β (TGF-β)18 and the proteasome inhibitor bortezomib.19 Although the role of NK cells in oncolytic adenovirus therapy has not been thoroughly explored, expression of Ad5 E1A protein can sensitize tumor cells to NK-mediated lysis,20 and several studies have implicated NK cells in the elimination of non-replicating E1-deleted adenovirus vectors.21,22

Here, we evaluated the role of NK cells in the efficacy of oncolytic adenoviral therapy in ovarian cancer. Species-specific replication of adenoviruses and the subsequent lack of in vivo immunocompetent model systems23 have hindered the understanding of immune responses to oncolytic adenoviral infections. To circumvent these shortcomings, we used primary NK cells isolated both from peripheral blood and ovarian cancer ascites to investigate the influence of NK cells in oncolytic adenoviral therapy in ovarian cancer. We show that NK cells augment the activity of oncolytic adenoviruses in a manner that is contact dependent and involves NK activating...
receptor DNAM-1 (DNAx accessory molecule-1). Furthermore, blockade of NK inhibitory receptor TIGIT also augments the effectiveness of oncolytic adenoviruses.

RESULTS

Adenovirus Is Unable to Infect NK-92 and Primary Hematopoietic Cells from Ovarian Cancer Ascites

The ability of human adenoviruses to infect human immune cells, including NK cells, was assessed using Ad-GFP, a non-replicating adenovirus type 5 encoding green fluorescent protein (GFP) under the control of the CMV (cytomegalovirus) immediate early promoter, d922-947 and NG-107, a GFP-encoding derivative of enadenotucirev. There was no detectable fluorescence in the established NK cell line NK-92 following Ad CMV GFP infection (Figure S1A), in contrast to a panel of ovarian cancer (OC) cells (p = 0.0002). Adenoviral protein expression was detected by immunofluorescence in TOV21G, but not peripheral blood NK (pNK) cells, after infection with d922-947 (Figure S1B). Similarly, there was no detectable GFP fluorescence in CD45+ populations isolated from peripheral blood mononuclear cells (PBMCs) and ascites after incubation with Ad CMV GFP (Figure S1C), nor in pNK after incubation with NG-107 (Figure S1D). Thus, effects seen in subsequent experiments did not result from direct infection of immune cells by adenovirus.

Upregulation of CD69, CD107a, and Interferon-γ (IFN-γ)

Because NK-92 cells have high basal expression of degranulation marker CD107a (Figure S2), the influence of oncolytic adenoviral infection on NK cell activation status was assessed in pNK cells. Co-culture of pNK with d922-947-infected TOV21G and OVCAR4 cells led to upregulation of both CD69 and CD107a on pNK compared to mock-infected controls (Figure 1A). The CD69 average MFI (mean fluorescence intensity) increased significantly for both TOV21G (mean fold change 2.1, 95% confidence interval (CI) 1.4–2.7 p = 0.0022) and OVCAR4 (mean fold change 1.4, 95% CI 1.1–1.6, p = 0.0023). CD107a positivity also increased significantly from 4.2% to 11.2% for TOV21G (mean difference 7.0%, 95% CI 4.1%–9.9%, p = 0.001), a similar, albeit non-significant, trend was observed for OVCAR4 (Figure 1B). There were also significant increases in IFN-γ levels in cell-free supernatants following pNK co-culture (Figure 1C)—IFN-γ concentration increased 7-fold (median 22 pg/mL to 157 pg/mL, p = 0.03, n = 6 independent experiments) for TOV21G and nearly 4-fold (median 29 pg/mL to 114 pg/mL, p = 0.003) for OVCAR4 (Figure 1C).

Similarly, co-culture of pNK with enadenotucirev-infected TOV21G also led to a significant increase in CD69 expression (mean fold change 1.8, 95% CI 1.2–2.4, p = 0.0162) and IFN-γ release (median increase 3,679 pg/mL, p = 0.03) on pNK, as well as a trend toward CD107a upregulation (Figures 1B and 1C). Co-culture with enadenotucirev-infected OVCAR4 also led to increases in CD69 (Figure 1B, p = 0.034) and IFN-γ (Figure 1C, p < 0.0001) on pNK, although not CD107a. The observed NK activation for both viruses was dependent on contact with virus-infected OC cells, as exposure to conditioned medium alone did not upregulate CD69 or CD107a, nor did it increase IFN-γ production in any pNK group assessed (Figure S3).
target cells (Figures 4C and 4D), suggesting that direct contact between NK and virus-infected malignant cells was essential. To assess further whether cell-cell contact was a pre-requisite for the augmented NK anti-tumoral cytotoxicity, we compared cell death in \textit{d}l922-947-infected cells in transwell inserts under different conditions (Figure 4E). Consistent with Figure 3, in the transwells in which NK cells and virus-infected TOV21G cells were in direct contact, there was significantly more cell death compared to virus infection alone (Figure 4E, group 1 versus 2; mean difference = 15.3%, 95% CI 6.8%–23.7%, \( p = 0.007 \)). However, where there was no direct contact (Figure 4E, group 3 versus 4), there was no difference in the proportion of dead TOV21G cells within the transwell inserts, indicating a lack of contact-independent killing.

\textbf{Expression of Selected NK Ligands and Receptors after Oncolytic Adenovirus Infection}

MHC class I was downregulated on the surface of OC cells after infection with \textit{d}l922-947 but not Ad3/11 enadenotucirev (Figure 5A; Figure S6A; \( p = 0.039 \)) or non-replicating Ad5 adenovirus Ad LM-X (data not shown). We found no change in CD112, CD155 (Figure 5A),
MICA/B, or CD58 (data not shown) expression following d922-947 infection. In addition, using recombinant human Fc chimeras (Figure 5B), we did not detect any change in expression of ligands that bind to NKG2D, Nkp30, Nkp44, and Nkp46 on TOV21G and OVCAR4 after infection with either d922-947 or enadenotucirev (Figure 5C; Figure S6B).

Despite the absence of changes in CD112 and CD155 expression, we observed a significant increase in binding of DNAM-1 recombinant human Fc chimeras on TOV21G following d922-947 infection (Figure 5D; p = 0.024), but not enadenotucirev infection. A similar trend was observed in OVCAR4, although this did not reach statistical significance. To explore this further, we analyzed the expression of the paired receptors DNAM-1 and TIGIT, as well as CD96 and Nkp46, on pNK cells following co-culture with TOV21G cells (both uninfected or adenovirus-infected) or conditioned medium (Figures 6A and 6B; Figure S7). There was no significant difference between the expression of NK receptors CD96 and Nkp46 (Figure S7). However, co-culture of pNK with OC significantly reduced the expression of DNAM-1 (p = 0.04, Figures 6A and 6B) and enhanced the expression of TIGIT (p < 0.0001, Figures 6A and 6B) compared to conditioned medium, independent of virus infection.

The Role of DNAM-1 and TIGIT in NK Cytotoxicity against d922-947-Infected Cells

Finally, we evaluated the effect of DNAM-1 and TIGIT blockade on NK cell activity against d922-947-infected cells (Figures 6C and 6D). As previously, the addition of pNK augmented cytotoxicity of d922-947 in both TOV21G and OVCAR4 cells. DNAM-1 blockade alone, in the absence of NK cells, had no effect on d922-947 efficacy in either cell line. DNAM-1 blockade also had no significant effect on the efficacy of NK cells against uninfected cancer cells. In contrast, DNAM-1 blockade consistently reduced cytotoxicity in both d922-947-infected TOV21G (decrease in TAUC 11,319 units; p = 0.008) and OVCAR4 (decrease in TAUC 1,271 units; p = 0.03) when co-cultured with NK cells. We also evaluated the effect of TIGIT blockade on NK cytotoxicity against OV-infected cells (Figure 6E), with mock-infected and NK-only groups as controls (Figure S8). Compared to NK alone, the addition of TIGIT blockade significantly augmented NK cytotoxicity against d922-947-infected TOV21G (increase in TAUC 6,532 units, p = 0.003). A similar trend was observed for enadenotucirev-infected TOV21G (increase in TAUC 5,069 units), although the difference did not reach statistical significance.

DISCUSSION

Oncolytic viruses have the ability to induce potent immune responses, and recent data suggest that this could prime tumor cells for immune checkpoint blockade. However, NK cells have the ability to eliminate both virus-infected cells and malignant cells rapidly, which may also prevent the spread of OVs and reduce OV activity. It was previously shown that NK cells could impede anti-tumor activity of an oncolytic HSV vector in vivo via Nkp30 and Nkp46. In this study, we explored the role of NK cells in the activity of two different oncolytic adenoviruses, d922-947 and enadenotucirev, using primary NK cells isolated from peripheral blood and ovarian cancer ascites—the use of primary cells was necessary given the species specificity of adenovirus replication.

Overall, our results indicate that d922-947 infection led to NK activation, as demonstrated by upregulation of CD69 and CD107a expression, as well as IFN-γ production. Enadenotucirev infection also promoted IFN-γ release and CD69 expression, with only modest changes in CD107a. For both viruses, this activation was contact-dependent, as exposure to cell-free conditioned medium from adenovirus-infected OC cells did not significantly increase CD69, CD107a, or IFN-γ.

Our results also indicate that all NK cells tested (NK-92, pNK, and ascites NK cells) augmented oncolytic adenovirus anti-tumor activities, compared to either NK cells or oncolytic adenovirus alone. This increase in cell death was observed both by conventional flow cytometry at a single time point and by time-lapse microscopy over 24 h. The changes were more pronounced for d922-947 than enadenotucirev, consistent with the greater changes in NK activation markers observed. The effect was generally greater for pNK cells than was observed in the two ascites NK cells tested. It is possible that ovarian cancer ascites NK cells are less cytotoxic or have a more suppressed phenotype than pNK—previous evidence suggested that expression of activating receptors may be reduced on ascites NK cells in ovarian cancer, leading to impaired cytotoxicity. However, further experiments with a larger number of ascites samples would be required to understand more fully the activation status of ascites NK cells and their responsiveness to oncolytic virus infection. Like the NK cell activation, NK killing of oncolytic adenovirus-infected cells was contact-dependent—soluble factors released from virus-infected cells alone were insufficient to induce additional NK killing of uninfected target cells.

Infection by a wide variety of viruses can influence NK activity via inhibitory and activating NK receptors. Consistent with previous reports, we found that MHC class I molecules were downregulated after Ad5 oncolytic adenovirus infection, which could reduce anti-tumor immune responses. In contrast, MHC class I molecules were unchanged after Ad3/11 enadenotucirev and non-replicating Ad5 adenovirus infections. However, we saw no changes in MICA/B, which contrasts with previous data that suggested that the adenovirus...
A

TOV21G

- df922-947/pNK
- Mock/pNK
- df922-947/No NK
- Mock/No NK

B

OVCAR4

- df922-947/pNK
- Mock/pNK
- df922-947/No NK
- Mock/No NK

C

% dead of CD45-cells

- df922-947/pNK (10:1)

D

TOV21G - patient 1

- df922-947/aNK
- Mock/aNK
- df922-947/No NK
- Mock/No NK

TOV21G - patient 2

- df922-947/aNK
- Mock/aNK
- df922-947/No NK
- Mock/No NK

(legend on next page)
We investigated the paired NK receptors DNAM-1 and TIGIT as DNAM-1 has previously been shown to play a key role in elimination of both malignant and CMV-infected cells by NK cells. In ovarian cancer specifically, the DNAM-1/CD155 interaction may be crucial for NK-mediated lysis. We found that DNAM-1 expression was decreased and TIGIT expression increased on NK cells following co-culture with ovarian cancer cells, independent of virus infection. However, the potential inhibitory effect of this change on NK was partially overcome by dn922-947 infection as DNAM-1 ligands were significantly upregulated after dn922-947 infection, as demonstrated by increased binding to a DNAM-1 Fc-chimera. Critically, we also found that DNAM-1 blockade significantly, albeit incompletely, reduced pNK cytotoxicity against dn922-947-infected malignant cells, but not against mock-infected cells.

Surprisingly, we were not able to demonstrate an increase in expression of the two main ligands for DNAM-1, CD155 (the Polio Virus Receptor/Nectin-like protein 5) and CD112 (Nectin-2), by flow cytometry following either dn922-947 or enadenotucirev infection. This suggests either the presence of additional DNAM-1 ligands that are upregulated following adenovirus infection or that adenovirus proteins may be able to bind to DNAM-1 causing NK cell activation. A preliminary assessment of the 36 adenovirus type 5 peptides identified three (III, IVa2, and V) with at least partial alignment with the consensus amino acid residues of DEGNYTC critical for DNAM-1 interactions in Nectin/Nectin-like proteins, including CD112 and CD155, and thus potentially able to activate DNAM-1 (Figure S9). The interactions between viral and bacterial proteins and NK receptors have not been thoroughly investigated, and a systematic exploration of individual adenovirus proteins will be required to address these results fully. However, it has been shown that Fap2 protein derived from Fusobacterium nucleatum present in human colon can interact with TIGIT to inhibit NK cytotoxicity against colon cancer.

We also found that TIGIT blockade augmented pNK cytotoxicity, reinforcing the importance of the DNAM-1/TIGIT axis in NK responses against cancer cells infected with oncolytic adenoviruses. TIGIT is an inhibitory NK receptor that competes with DNAM-1 and CD96 for ligand-binding. TIGIT is expressed on both T and NK cells, where its expression is associated with T cell exhaustion phenotypes. It is also upregulated in human malignancies and a number of anti-TIGIT antibodies (e.g., etigilimab/OMP-313M32, MTIG7192A, and AB154) are now being evaluated in early phase clinical trials as anti-cancer agents.

In summary, oncolytic adenovirus-infected ovarian cancer cells were able to activate human NK cells and augment NK cytotoxicity in vitro. For dn922-947, an Ad5 oncolytic adenovirus, this augmented cytotoxicity was contact-dependent and involved modulating the interactions between activating NK receptor DNAM-1 and virus-infected malignant cells. Although enadenotucirev, an oncolytic group B adenovirus identified by its ability to propagate selectively in carcinoma cells and kill them rapidly, also augmented NK cytotoxicity, the effects were less marked than with dn922-947 infection and did not appear to be associated with DNAM-1. Further research will be required to evaluate additional NK receptor-ligand pathways involved in the augmented NK cytotoxicity observed, particularly for enadenotucirev. Our results highlight the lack of direct comparison of the efficacy of different oncolytic viruses and the importance of understanding the specific immune responses against each oncolytic virus for maximizing therapeutic benefits. Our demonstration that blockade of the paired NK inhibitory receptor TIGIT further augmented NK cytotoxicity against OV-infected cells suggests that the combination of oncolytic adenovirus and TIGIT blockade may be a viable treatment strategy in ovarian cancer.

**MATERIALS AND METHODS**

**Cell Lines and Tissue Culture**

Ovarian cancer cell lines OVCAR4 (NCI, Frederick, MA), TOV21G (Fran Balkwill, Barts Cancer Institute, London, UK), erythroleukemia cell line K562 (Vignir Helgason, University of Glasgow, Glasgow, UK), and human NK cell line NK-92 (ATCC, Manassas, VA) were incubated at 37°C in 5% CO2. OVCAR4 and TOV21G were maintained in DMEM with 10% FBS, 2 mM L-Glutamine, and 100 μg/mL penicillin/streptomycin. NK-92 cells were maintained in MEM-alpha with 12.5% FBS, 12.5% horse serum, 2 mM L-Glutamine, and 5 ng/mL interleukin-2 (IL-2). K562 were maintained in RPMI with 10% FBS plus 2 mM L-Glutamine, and 100 μg/mL penicillin/streptomycin.

All lines were tested regularly for mycoplasma infection. All cell lines and tissue culture reagents, media, and antibiotics were from Sigma-Aldrich (St. Louis, MO). The human NK cell line NK-92 was a gift from Dr. Vignir Helgason, University of Glasgow, Glasgow, UK. Ovarian cancer cell lines OVCAR4 (NCI, Frederick, MA), TOV21G (Fran Balkwill, Barts Cancer Institute, London, UK), human, and human NK cell line NK-92 (ATCC, Manassas, VA) were incubated at 37°C in 5% CO2. OVCAR4 and TOV21G were maintained in DMEM with 10% FBS, 2 mM L-Glutamine, and 100 μg/mL penicillin/streptomycin. NK-92 cells were maintained in MEM-alpha with 12.5% FBS, 12.5% horse serum, 2 mM L-Glutamine, and 5 ng/mL interleukin-2 (IL-2). K562 were maintained in RPMI with 10% FBS plus 2 mM L-Glutamine, and 100 μg/mL penicillin/streptomycin.
were isolated, resuspended in RPMI with 10% FBS plus 2 mM L-Glutamine and 100 μg/mL penicillin/streptomycin, and used immediately without additional IL-2 or IL-15.

Ethics Statement
Use of PBMCs isolated from samples from healthy blood donors was approved by the Scottish National Blood Transfusion Service (reference number 15-35). All donors gave written consent. Ascites samples from patients with ovarian cancer undergoing drainage for clinical purposes were collected under authority of the NHS Greater Glasgow and Clyde Biorepository (UK Health Research Authority Research Ethics Committee reference 10/S0704/60). Use of ascites samples for this project was then authorized by the NHS Greater Glasgow and Clyde Biorepository Access Committee (reference 16/WS/0207). All patients gave written consent and samples were anonymized.

Isolation of Peripheral Blood and Ascites-Derived NK Cells
pNK cells were isolated from PBMCs using EasySep Human NK Cell Enrichment Kits (19055; StemCell Technologies, Canada) according to the manufacturer’s instructions. Human ovarian cancer ascites samples were centrifuged at 2,500 rpm for 15 min at 18°C (JS-4.2, Beckman-Coulter, USA) in 250 mL centrifuge tubes. The cell pellet was enriched using EasySep Human NK Cell Enrichment Kits before fluorescence-activated cell sorting (FACS) based on extracellular cell surface markers of NK cells (CD45+CD3−CD56+). The purity of primary NK cells (>90%) was confirmed by flow cytometry.

Adenoviruses
The E1A CR2-deleted Ad5 vector d922-947 and enadenotucirev, an Ad3/Ad11p chimeric virus generated by directed evolution, have both been previously described. Enadenotucirev was provided by PsiOxus Therapeutics (Oxford, UK). Ad CMV GFP is an E1-deleted replication-deficient adenovirus type 5 vector expressing eGFP under the CMV immediate/early promoter. Reporter
enadenotucirev-based virus NG-107 (SSA promoter) also encodes eGFP and was generated by Marino et al. Ad LM-X, a replication-defective adenovirus type 5 has been described previously. Viruses were expanded in 293 cells before cesium chloride (CsCl) purification, as previously described. Viruses were then quantified by measuring particle counts and tissue culture inhibitory dose 50% (TCID50) assays. In all infection experiments, multiplicity of infection (MOI) was defined as plaque-forming units (pfu)/cell. Cells were infected for 48 h prior to co-culture with NK cells for a further 24 h. MOIs were selected based upon dose response curves with the chosen cell lines as determined by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays post-infection (Figures S10 and S11), as previously described.

**Infectability of NK Cells**

NK-92, PBMCs, cells from ascites, purified pNKs, and OC lines (including TOV21G) were incubated with Ad CMV GFP (MOI 10), db922-947 (MOI 10), and NG-107 (MOI 100) for 48 h before flow cytometric and immunofluorescence assessment of infectability. Because there is not a GFP-encoding derivative of db922-947, adenovirus protein expression was assessed by immunofluorescence using an anti-adenovirus primary antibody (Ab36851; 1 in 100; Abcam, UK). Cells were counterstained with DAPI. Imaris software (Version 9.3.1; Bitplaine, Switzerland) was used to identify immunofluorescent cells. Briefly, individual cells were identified by DAPI (4',6-diamidino-2-phenylindole) staining and counted. For each experiment, the fluorescence intensity (GFP or Alexa Fluor 594) of mock-infected pNK cells was used to define the minimum fluorescence intensity of positive (i.e., infected) cells. The same algorithm was then applied to all images in the same experiment and positive/infected cells were identified and counted. To allow direct comparisons between groups and replicates, we calculated percentages of positive/infected cells.

**Evaluation of CD107a, CD69, and NK Receptors**

For co-culture experiments, TOV21G and OVCAR4, with or without db922-947 (MOI 10, 48 h) and enadenotucirev (MOI 100, 48 h) infection, were incubated with 5 × 10^5 PBMCs from healthy donors in 96-well plates at 1:1 ratio in a total volume of 100 µL. Similarly, for the conditioned medium experiments, cell-free conditioned medium from db922-947 (MOI 10, 48 h) and enadenotucirev (MOI 100, 48 h) infected TOV21G and OVCAR4 was incubated with 5 × 10^5 PBMCs from healthy donors in 96-well plates in a total volume of 100 µL.

To collect cell-free conditioned medium, we plated 10^6 OC cells (OVCAR4, TOV21G) on 6 cm plates before infection with db922-947 (MOI 10) or enadenotucirev (MOI 100) in a total volume of 1.5 mL. Cell-free medium was collected 48 h after infection. For CD107a and CD69, the mixtures were incubated for 5 h at 37°C in the presence of monensin (GolgiStop, 1:1,000, cat number: 554724,
BD Biosciences, Berkshire, UK) and conjugated antibodies for CD3, CD56, and degranulation marker CD107a or activation marker CD69 in a total volume of 150 μL. Cells were washed and stained by fixable viability dye before fixation and flow cytometric evaluation. For cell surface NK receptors NKp46 (clone 9E2), CD96 (clone N9K239), DNAM-1 (clone 11A8), and TIGIT (clone A15153G), the mixtures were incubated for 18 h at 37°C before flow cytometric evaluation.

IFN-γ Detection by ELISA
In co-culture experiments (CC), 10^4 target cells (TOV21G and OVCA4 infected with d922-947 [MOI 10] or enadenotucirev [MOI 100] for 48 h) were incubated with 10^5 pNK cells or no-NK culture medium (RPMI with 10% FBS) for 24 h in a 96-well plate at a total volume of 200 μL (ET ratio 10:1). In the conditioned medium experiments (CM), cell-free conditioned medium from mock-infected or virus-infected cells was added to 10^5 pNK or no-NK culture medium (RPMI with 10% FBS) for 24 h in a 96-well plate at a total volume of 200 μL. At the end of the incubation period (24 h) for both groups (CC and CM), the plate was centrifuged (430 g, 5 min), and the supernatant collected for IFN-γ quantification by ELISA (Human IFN-γ ELISA MAX Deluxe kit, cat number 430104; BioLegend, San Diego, CA), according to the manufacturer’s instructions.

Assessment of NK Cytotoxicity by Live Cell Analysis System
NK-92, pNK, or ascites NK cells were co-cultured with d922-947-infected (MOI 10, 48 h post-infection), enadenotucirev-infected (MOI 100, 48 h post-infection), mock-infected TOV21G and OVCAR4 or conditioned medium from each group at an effector-to-target (ET) ratio of 10:1 in flat-bottom 96-well plates in triplicate at 3,000 cells per well. Fluorescent CytoTox nucleic acid dye was used for identification of dead cells. Images were assessed using an IncuCyte Live Cell Analysis System (Essen Biosciences, Ann Arbor, MI) to identify the dead cells (as fluorescent objects) in each image (two 10× magnification images from different areas per well were captured every hour). Dead NK cells were excluded from analyses based on size (the minimal surface area for a fluorescent object to be included was 125 μm^2). The TAUC of fluorescent object counts over time was used to quantify overall NK killing. Target-only and NK-only controls were routinely used for these experiments.

Assessing NK Cytotoxicity by Flow Cytometry
TOV21G were plated in 24-well plates at 10^4 cells per well. After overnight incubation, cells were either mock-infected or infected with d922-947 (MOI 10), 48 h post-infection, NK-92 or human pNK were added (ET ratio of 10:1). Cells were harvested after 18-h co-culture, washed once and stained with surface marker CD45 for NK cells (Clone 2D1, Biolegend, San Diego, CA) and fixable viability dye (cat number 423113, Biolegend, San Diego, CA). Cell death in CD45-negative target TOV21G cells was determined by flow cytometry. Target-only and NK-only controls were also used in these experiments.

NK-Mediated Killing of Uninfected Tumor Cells
Target TOV21G and OVCAR4 cells (2 × 10^4/well) were plated on 12-well plates. After mock, d922-947 (MOI 10, 48 h) or enadenotucirev (MOI 100, 48 h) infection, pNK (ET ratio 5:1) or no-NK culture medium (negative control) was added to each well. Uninfected cells (TOV21G and OVCAR4, 2 × 10^4/well) were marked by CellTracker Green CMFDA Dye (2 μM, C7025, Thermo Fisher Scientific, USA) and added to target cells 4 h after initiation of NK/infected target cell co-culture. After a further 18-h incubation, supernatants and cells were collected and centrifuged (430 g for 5 min). Viability of uninfected CellTracker green cells was determined by flow cytometry. Additional NK-mediated killing was calculated by subtracting the percentage of cell death in the no-NK controls from that in the pNK groups.

Transwell Assays to Assess NK Bystander Killing
Contact-dependence of pNK cytotoxicity against d922-947-infected TOV21G was evaluated by assessing cell death of d922-947-infected TOV21G in 0.4 μm transwells. TOV21G (10^4/well) were plated on the bottom of a 12-well plate and on the 0.4-μm-pore polycarbonate 12-well transwell inserts (12 mm membrane diameter; cat number: 3401, Corning, USA). After mock or d922-947 infection (MOI 10, 48 h), pNK (10^2; ET 10:1), or no-NK culture medium (negative control) was added to the bottom of the well. After an 18-h incubation, the inserts were carefully removed without spillage into a separate 12-well plate. The supernatants and trypsinated TOV21G of each group were combined and centrifuged (430 g for 5 min) before staining with viability dye and CD45 antibody (Clone HI30; Biolegend, San Diego, CA). Cell death in CD45-negative target TOV21G cells was determined by flow cytometry.

Recombinant Human Fc Chimera Protein and Flow Cytometry for Detection of NK Ligands
As multiple NK ligands can bind to a single NK receptor, NK ligand expression on infected OC cells was evaluated using recombinant human Fc chimera proteins. Recombinant human Fc chimera proteins consist of human immunoglobulin G1 (IgG1) and the relevant binding portion of the proteins of interest. These binding portions can bind with multiple relevant NK ligands of the corresponding NK

Figure 6. DNAM-1 Blockade Attenuates and TIGIT Blockade Augments NK-Mediated Cytotoxicity against Adenovirus-Infected Cells
The changes of NK receptors on pNK after exposure to adenovirus-infected TOV21G or their conditioned media were evaluated by flow cytometry. (A) Summary analyses of independent experiments (n = 5) for DNAM-1 (left) and TIGIT (right) expression. (B) Representative images of DNAM-1 (left) and TIGIT (right) expression (Mann-Whitney U tests; CC, co-culture; CM, conditioned-medium). pNK were co-cultured with d922-947-infected cells with or without a blocking anti-DNAM-1 antibody (10 μg/mL) and assessed by time-lapse microscopy. (C) Representative data of fluorescent object counts over time for TOV21G (left) and summary data (n = 5) of TAUC for TOV21G (right) and (D) OVCAR4 (n = 3) are shown (one-way ANOVA with multiple comparisons test). (E) pNK were co-cultured with OV-infected TOV21G cells with or without a blocking anti-TIGIT antibody (20 μg/mL) and assessed by time-lapse microscopy (n = 5, each line represents a unique donor; also see Figure S8).
receptors, e.g., DNAM-1. As the affinity of these chimeric proteins and target ligands could be influenced by treatment conditions, the fold change in MFI between relevant Fc chimera and control Fc protein was used to compare differences between groups.

Cells were stained with recombinant human Fc chimera proteins (R&D Systems, Minneapolis) or conjugated antibodies (all from Biologend, San Diego, CA) against MHC class I proteins (clone W6/32, CD112 (clone TX31), and CD155 (clone SKIL4). As the antibody against human Fc-protein was conjugated with biotin, tertiary antibody staining was assessed with Streptavidin-PE in 50 μL at 1:1,000 for 30 min at 4°C–8°C in the dark (Figure 5B, cat number 405203, Biologend, San Diego, CA). Cells were washed twice with 150 μL of FACS buffer, centrifuged (430 g, 5 min, 4°C) and supernatant discarded.

DNAM-1 and TIGIT Blockade

Human NK cells were rested in culture medium for 1 h, with or without anti-DNAM-1 (MAB666, R&D Systems, Minneapolis, MN; final concentration 10 μg/mL) or anti-TIGIT (MAB78981, R&D Systems, Minneapolis, MN; final concentration 20 μg/mL) antibody, before co-culture with target cells (with or without OV infections). Cell-free medium with appropriate antagonists and no target cell controls was routinely used as control.

Statistical Analyses

All statistical analyses were performed using Prism (v8.0, GraphPad, La Jolla, CA). Data are presented as mean ± SEM unless otherwise stated. Paired analyses (one-way ANOVA with multiple comparison tests, t tests, or their non-parametric equivalent) were used for analysis of repeated experiments, and p < 0.05 was considered significant throughout. Unless otherwise stated, each symbol/point represents the average value of an independent experiment. In all figures, ns = not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.omto.2020.02.001.

AUTHOR CONTRIBUTIONS

Conceptualization, E.Y.L.L., I.A.M. Data curation, E.Y.L.L., I.A.M., D.P.E., S.D., M.F., P.S., J.N., S.M. Formal analysis, E.Y.L.L., I.A.M. Funding acquisition, E.Y.L.L., I.A.M., G.G., D.M.D. Methodology, E.Y.L.L., P.R.K., C.H., L.M.C., D.M.D., G.G. Project administration, E.Y.L.L., I.A.M. Resources, C.H., K.F., D.P.E., S.D., M.F., P.S. Supervision, I.A.M., D.M.D., G.G. Visualization, E.Y.L.L., I.A.M. Writing – original draft, E.Y.L.L., I.A.M. Writing – review & editing, all authors.

CONFLICTS OF INTEREST

K.F. is an employee of PsiOxus Therapeutics Limited. The remaining authors declare no competing interests.

ACKNOWLEDGMENTS

This study was funded by the Wellcome Trust (grants 102746/Z/13/Z to E.Y.L.L. and 110091 to D.M.D.), Cancer Research UK (grants C16420/A12995 and C608/A15973 to I.A.M.), the University of Glasgow, the Beatson Cancer Charity (grant 15-16-051 to I.A.M.), and the National Institute for Health Research Imperial Biomedical Research Centre (grant P74580 to I.A.M.). Enadenotucirev was supplied by PsiOxus Therapeutics. The funders played no part in the design of experiments nor in the analysis of data. The authors also acknowledge infrastructure support from the Glasgow Experimental Cancer Medicine Centre, the Glasgow Cancer Research UK Centre, and the Ovarian Cancer Action Research Centre.

REFERENCES

1. Prestwich, R.J., Ilett, E.J., Errington, F., Diaz, R.M., Steele, L.P., Kotkite, T., Thompson, J., Galivo, F., Harrington, K.J., Pandha, H.S., et al. (2009). Immune-mediated anti-tumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin. Cancer Res. 15, 4374–4381.
2. Bourgeois-Daigneault, M.-C., Roy, D.G., Atiken, A.S., El Sayes, N., Martin, N.T., Varette, O., Falls, T., St-Germain, L.E., Pelin, A., Lichty, B.D., et al. (2018). Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Sci. Transl. Med. 10, eaao1641.
3. Samson, A., Scott, K.J., Taggart, D., West, E.J., Wilson, E., Nuovo, G.J., Thomson, S., Corns, R., Mathew, R.K., Fuller, M.J., et al. (2018). Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Sci. Transl. Med. 10, eaaw7577.
4. Melcher, A., Parato, K., Rooney, C.M., and Bell, J.C. (2011). Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol. Ther. 19, 1008–1016.
5. Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D.D., and Krim, D.H. (1997). ONX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemo-therapeutic agents. Nat. Med. 3, 639–645.
6. Bauerschmitz, G.J., Lam, J.T., Kanerva, A., Suzuki, K., Nettelbeck, D.M., Dmitriev, I., Krasnykh, V., Mikheeva, G.V., Barnes, M.N., Alvarez, R.D., et al. (2002). Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res. 62, 1266–1270.
7. Wang, X., Su, C., Cao, H., Li, K., Chen, J., Jiang, L., Zhang, Q., Wu, X., Jia, X., Liu, Y., et al. (2008). A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers. Mol. Cancer Ther. 7, 1598–1603.
8. Guo, J., and Xin, H. (2006). Chinese gene therapy. Splicing out the West? Science 314, 1232–1235.
9. Ingemarsdotter, C.K., Tookman, L.A., Browne, A., Pirlo, K., Cutts, R., Chelela, C., Khrurum, K.F., Leung, E.Y., Dowson, S., Webber, L., et al. (2015). Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control. Mol. Oncol. 9, 791–805.
10. Lockley, M., Fernandez, M., Wang, Y., Li, N.F., Conroy, S.E., Lemoine, N.R., et al. (2006). Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with adenovirus wild-type, bioluminescence monitoring and intraoperative delivery in icodextrin. Cancer Res. 66, 989–998.
11. Kuhn, I., Harden, P., Bazoum, M., Chartier, C., Nye, J., Thorne, S., Reid, T., Ni, S., Lieber, A., Fisher, K., et al. (2008). Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS ONE 3, e2409.
12. McNich, I.A., Michael, A., Jayson, G.C., Glasspool, R.M., Brown, R., Fisher, K., et al. (2016). A phase I/II study of enadenotucirev, a chimeric Ad11/Ad3 oncolytic group B adenovirus, administered intraperitoneally (IP) in platinum-resistant epithelial ovarian cancer: Pharmacokinetic (PK) and tolerability data from phase I. J Clin. Oncol. 34, 5545.
13. Jost, S., and Altfeld, M. (2013). Control of human viral infections by natural killer cells. Annu. Rev. Immunol. 31, 163–194.
14. Marcus, A., Gowen, B.G., Thompson, T.W., Iannello, A., Ardolino, M., Deng, W., Wang, L., Shifrin, N., and Raulet, D.H. (2014). Recognition of tumors by the innate immune system and natural killer cells. Adv. Immunol. 122, 91–128.
15. El-Sherbiny, Y.M., Holmes, T.D., Wetherill, L.F., Black, E.V., Wilson, E.B., Phillips, S.L., Scott, G.B., Adair, R.A., Dave, R., Scott, K.J., et al. (2015). Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo. Clin. Exp. Immunol. 180, 98–107.

16. Alkayyal, A.A., Tai, L.H., Kennedy, M.A., de Souza, C.T., Zhang, J., Lefebvre, C., Sahi, S., Ananth, A.A., Mahmoud, A.B., Makrigiannakis, A.P., et al. (2017). NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine. Cancer Immunol. Res. 5, 211–221.

17. Alvarez-Breckenridge, C.A., Yu, J., Price, R., Wotjons, J., Pradarem, J., Mao, H., Wei, M., Wang, Y., He, S., Hardcastle, J., et al. (2012). NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat. Med. 18, 1827–1834.

18. Han, J., Chen, X., Chu, J., Xu, B., Meisen, W.H., Chen, L., Zhang, J., He, X., Wang, Q.E., et al. (2015). TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response. Cancer Res. 75, 5273–5282.

19. Yoo, J.Y., Jaime-Ramirez, A.C., Bolyard, C., Dai, H., Nallanagulagari, T., Wojton, J., Hurwitz, B.S., Relation, T., Lee, T.J., Lotze, M.T., et al. (2016). Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy. Clin. Cancer Res. 22, 5265–5276.

20. Routes, J.M., Ryan, S., Morris, K., Takaki, R., Cervenka, A., and Lanier, L.L. (2005). Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection. J. Exp. Med. 202, 1477–1482.

21. Zhu, J., Huang, X., and Yang, Y. (2008). A critical role for type I IFN-dependent NK cell activation in innate immune elimination of adenovirus vectors in vivo. Mol. Ther. 16, 1300–1307.

22. Zhu, J., Huang, X., and Yang, Y. (2010). NKG2D is required for NK cell activation and function in response to E1-deleted adenovirus. J. Immunol. 185, 7480–7486.

23. Young, A.M., Archibald, K.M., Tookman, L.A., Pool, A., Dudek, K., Jones, C., Tomic, A., Kvestak, D., Babic, M., Tsukerman, P., et al. (2016). Inflammatory monocytes and NK cells play a crucial role in DNAM-1-dependent control of cytomegalovirus infection. J. Exp. Med. 213, 1835–1850.

24. Carlsten, M., Björkström, N.K., Nordell, H., Bryceson, Y., van Hall, T., Baumann, B.C., Hanson, M., Schedvins, K., Küssling, R., Ljunggren, H.G., and Malmberg, K.J. (2007). DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res. 67, 1317–1325.

25. Liu, J., Qian, X., Chen, Z., Xu, G., Fang, Z., Zhang, R., Qi, J., Gao, G.F., and Yan, J. (2012). Crystal structure of cell adhesion molecule nectin-2/CD112 and its binding to immune receptor DNAM-1/CD226. J. Immunol. 188, 5511–5520.

26. Gur, C., Ibrahim, Y., Isaacscon, B., Yamin, R., Abed, J., Gamliel, M., Enk, J., Bar-On, Y., Staniesky-Kaynan, N., Coppenhagen-Glazer, S., et al. (2014). Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 42, 344–355.

27. Manieri, N.A., Chiang, E.Y., and Grogan, J.L. (2017). TIGIT: A Key Inhibitor of the Cancer Immunity Cycle. Trends Immunol. 38, 20–28.

28. Chan, C.J., Martinet, L., Gilfillan, S., Souza-Fonseca-Guimaraes, F., Chow, M.T., Town, L., Ritchie, D.S., Colonna, M., Andrews, D.M., and Smyth, M.J. (2014). The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat. Immunol. 15, 431–438.

29. Mazzarella, L., Duso, B.A., Trapani, D., Belli, C., D’Amico, P., Ferraro, E., Viale, G., and Curigliano, G. (2019). The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review. Eur. J. Cancer 117, 14–31.

30. Ilinvingworth, S., Di, Y., Buzon, M., Lei, J., Duffy, M.R., Alvis, S., Champion, B.R., and Brown, A.C.N. (2017). Development of a versatile oncolytic adenovirus with a therapeutic virus de...